Aesthetics nurse was 'stockpiling' medications, court hears
Nichola Hawes, 49, is on trial for alleged fraud and selling or supplying medicines, including drugs for weight loss and Botox, without proper prescriptions.
She runs Nichola Hawes Aesthetic Clinic on Groomsport Road in Bangor, County Down, and faces 31 charges, including fraud by false representation.
Giving evidence at at Downpatrick Crown Court on Thursday, Department of Health (DoH) pharmacist Aaron McKendry said: "The quantity may have indicated that it was not solely for the person it was prescribed for."
Mr McKendry that said while the clinic could have held medicines for specific patients or clients to be given to them during treatment, the way they had been ordered and the quantities found "suggested that they were for stock".
Mr McKendry said that a month before a box of medications had been delivered to Ms Hawes' client Jordan Cairns, he had been doing routine checks on private prescriptions at a specific pharmacy when he noticed an unusual amount of B12 prescriptions had been ordered by Ms Hawes.
Further inquiries at another pharmacy established that medications being ordered by Ms Hawes were being delivered to her clinic rather than to the patient, while a search of Ms Hawes' clinic uncovered boxes of medications without labels.
He explained that under the Human Medicines Act and associated regulations, a prescription-only medication should have a patient's name on it, who and when it was ordered by, and the dispensing pharmacist.
Many of the medicines found at Ms Hawes' clinic had no such labelling and while some of them did, Mr McKendry explained that under the Human Medicines Act it was only doctors and dentists who are allowed to keep a stock of medicines, not prescribing nurses.
The trial continues.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
10 hours ago
- Forbes
A Regulated Trip: What New Mexico's Psilocybin Law Means For Work
Magic mushrooms are now medicine in New Mexico. And that shift could have ripple effects in the workplace. This spring, Governor Michelle Lujan Grisham signed Senate Bill 219, the Medical Psilocybin Act, into law, making New Mexico the third state to legalize psilocybin for medical use. Unlike Oregon and Colorado, which adopted their psilocybin programs through ballot initiatives, New Mexico enacted its law through the legislative process. That distinction is more than procedural. It reflects an institutional shift toward integrating psychedelic therapy into the framework of state-managed healthcare. The law took effect on June 20, 2025, and requires full program implementation by December 31, 2027. With that, New Mexico becomes the first state to create a clinician-administered psilocybin program governed by medical oversight, not consumer access. As psilocybin therapy enters a regulated medical model, employers must now examine how psilocybin intersects with workplace safety, disability accommodation, and drug policy enforcement. Psilocybin's Reintroduction as Medicine Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms. Once ingested, it metabolizes into psilocin, which affects cognition, mood, and perception. Although it remains a Schedule I substance under federal law, psilocybin has reemerged over the past decade as a potential breakthrough therapy for severe mental health conditions. Peer-reviewed research continues to highlight its therapeutic potential in treating major depression, PTSD, substance use disorders, and end-of-life distress. New Mexico's legislation embraces this emerging science by establishing a medical-use program in which licensed clinicians, not dispensaries, administer psilocybin in approved therapeutic settings. The Department of Health is responsible for creating treatment protocols, licensing standards, clinician training, and oversight mechanisms. The Act also establishes both a research fund and a treatment equity fund to expand access and support clinical study. Psychedelic wellness expert Cesar Marin sees the program as a reflection of how far public understanding has evolved. 'We're not talking about the free‑wheeling psychedelic trips of the 1960s anymore,' Marin says. 'We're seeing most states consider or enact some form of psychedelic policy reform, and that momentum helps people feel more comfortable with the intentional, therapeutic use of psilocybin.' Qualifying conditions are narrowly defined to include treatment-resistant depression, PTSD, substance use disorder, and terminal illness. All treatment must occur in controlled environments with preparatory and integration sessions surrounding the administration of psilocybin. Psilocybin and psilocin are removed from the state's list of Schedule I controlled substances when used in accordance with the law, and services provided under the Act are exempt from New Mexico's gross receipts tax. Legal Protections Without Workplace Requirements The Medical Psilocybin Act offers strong protections for individuals operating within its boundaries. Licensed clinicians, producers, and qualified patients cannot be prosecuted under state law, and individuals on probation or awaiting trial may participate in treatment without jeopardizing their legal status. However, the Act stops short of granting any employment-based rights. It does not require employers to accommodate psilocybin use, nor does it prevent adverse action based on lawful participation in the program. That omission is deliberate and significant. While patients may legally participate in psilocybin-assisted therapy under state law, the federal classification of psilocybin as a Schedule I substance remains unchanged. And unlike medical cannabis laws in some states, New Mexico's psilocybin law provides no employment protections, no retaliation standard, and no accommodation framework. Still, employers should not assume the workplace will remain untouched. A New Compliance Challenge for Employers 'New Mexico legalizing medical psilocybin is a huge step toward bringing these treatments out of the shadows and into mainstream medicine,' says Marin. 'When folks see local leaders endorsing these programs, it lowers the fear factor and makes it easier for someone who's curious to explore them.' That shift in perception could soon reach the workplace. Employers may begin receiving accommodation requests from individuals participating in medically supervised psilocybin therapy for conditions like PTSD, treatment-resistant depression, or substance use disorder. And while psilocybin remains a federally controlled substance, the conditions it treats are often considered disabilities under the Americans with Disabilities Act (ADA). That means employers have a legal obligation to engage in the interactive process when an employee discloses a disability and requests accommodation, even if the employee's treatment involves a Schedule I substance like psilocybin. The ADA does not require employers to accommodate federally illegal drug use, but it does require them to consider accommodations related to the underlying condition. Employers are not obligated to tolerate on-the-job impairment or excuse safety violations. Still, if an employee reports off-duty participation in a licensed psilocybin program tied to a recognized condition, a flat denial without further inquiry could invite scrutiny under disability discrimination laws. Testing vs. Impairment: Where Policy Meets Practicality Psilocybin presents unique challenges when it comes to workplace drug testing. Unlike THC or opioids, psilocin, the active compound after ingestion, is not included in most standard employment drug panels. That means employers may be flying blind when it comes to detecting recent psilocybin use unless they specifically request an expanded panel. 'A person can be actively hallucinating due to psilocybin use and still pass a standard workplace drug test,' says Dr. Todd Simo, Chief Medical Officer at HireRight. 'Psilocin, the active compound, doesn't show up in most drug panels unless an employer specifically includes it. That's why training managers to recognize signs of impairment and providing a clear path to escalate reasonable suspicion are more effective strategies. For employers especially concerned, developing a reasonable suspicion panel that includes psilocybin and disclosing it to employees in advance can also help mitigate misuse.' Given that reality, employers may want to prioritize impairment-based enforcement strategies over reliance on traditional drug screening. While testing has its place, especially in post-accident investigations or in regulated industries, training supervisors to recognize signs of real-time impairment and respond consistently under internal policy is likely a more practical approach for most workplaces. Preparing for Disclosure and Dialogue Employers should take this opportunity to review and, where necessary, revise internal policies addressing drug and alcohol use, workplace impairment, and reasonable accommodations. Clarity around off-duty substance use and on-duty safety expectations will be essential. HR teams should also ensure that accommodation request procedures are equipped to handle emerging treatment disclosures, particularly where mental health conditions are involved. Equally important is creating an environment in which employees feel safe discussing mental health. Psilocybin's path to medical legitimacy mirrors, in many ways, the evolution of medical cannabis and broader mental health parity. For employers, staying ahead of these developments will require not only legal awareness but organizational empathy. The Bigger Picture New Mexico's Medical Psilocybin Act signals more than therapeutic access. It reflects a policy evolution, one where lawmakers, not just voters, are beginning to treat psychedelic medicine as a legitimate part of behavioral healthcare. The state's approach shifts the narrative from stigma to structure, putting psilocybin in the hands of trained clinicians operating under medical oversight. And while the law places no new obligations on employers, it surfaces a timely question: what does it mean to support mental health in a world where the frontier of treatment is changing? For employers, that shift invites action. It's time to revisit drug policies, reconsider testing strategies, and refine accommodation practices. As state-level momentum builds around psychedelics, employers don't need to endorse these therapies, but they do need to understand them. Because in the modern workplace, curiosity can be a better compliance strategy than surprise.
USA Today
a day ago
- USA Today
Woman accused of buying Lamborghini, plastic surgery with Medicaid fraud funds
A woman dubbed the "Medicaid millionaire from Slidell" has been arrested after officials said she lied about her income to get Medicaid, which allegedly paid for luxury vehicles and plastic surgery. Candace M. Taylor, 35, was arrested on Monday, July 28 in connection with a government benefits fraud scheme, Louisiana Attorney General Liz Murrill said in a news release. Taylor's arrest comes after someone with the state's Department of Health filed a complaint with the Louisiana Bureau of Investigation, the attorney general's office said. She allegedly spent the money between 2021 and 2024, according to the attorney general's office. She was booked on July 28 into the East Baton Rouge Parish Prison, and the investigation is ongoing, the attorney general's office added. As of Thursday, July 31, it is unclear whether Taylor retained a defense attorney. Where did the money go? According to Murrill's announcement of the charges, Taylor allegedly: She also shared proof of her purchases on social media, the attorney general's office said. How did authorities find out about Taylor's alleged purchases? The Louisiana Department of Health contacted the criminal investigative division of the state's Department of Justice with a complaint about Taylor's behavior, informing them that she committed Medicaid Recipient Fraud. According to the state Department of Health, Taylor underreported her income to receive Medicaid benefits. The attorney general's office said the timeline looked like this: Taylor's multiple businesses generated over $9M What helped authorities piece the case together was looking at Taylor's tax records and social media. Once investigators subpoenaed her tax records from the Louisiana Department of Revenue, agents learned she had bought a Lamborghini and paid for other luxury items and services, the attorney general's office said. In 2020, despite being approved for Medicaid and claiming no income, Taylor's accounts showed deposits of $480,994.09, and over $325,000 of that came from her businesses, the attorney general's office said. Between January 2020 and December 2024, Taylor's businesses generated over $9.5 million in revenue, according to Murrill's office. Saleen Martin is a reporter on USA TODAY's NOW team. She is from Norfolk, Virginia – the 757. Email her at sdmartin@
NBC News
2 days ago
- NBC News
1 dead, 22 sick from Legionnaires' cluster in Harlem, health officials say
A person has died and nearly two dozen people have fallen ill as part of a Legionnaires' cluster in Harlem, according to city health officials. The disease was initially detected on on July 25; since that time, one person has died and 22 have been diagnosed, the New York City Health Department said Wednesday. There were no details immediately available regarding the person who died as a result of the illness. Legionnaire's, a type of pneumonia, is caused by the bacteria Legionella, which grows in warm water. The cases from the cluster have been found in five Harlem ZIP codes: 10027, 10030, 10035, 10037 and 10039, along with the bordering communities, according to health officials. All cooling towers that are operating in the impacted area have been sampled, and the Health Department has told owners of buildings where positive results were found to initiate remediation within a day. Those who have been in the impacted area since late July and have been experiencing flu-like symptoms, fever, cough or difficulty breathing should seek medial attention immediately, according to the Health Department. Legionnaires' disease is not transmitted from person to person, and is treatable with antibiotics. It spread by breathing in water vapor containing the Legionella bacteria. Conditions for the bacteria to grow are favorable in things like cooling towers, whirlpool spas, hot tubs, humidifiers, hot water tanks and condensers of large air-conditioning systems. An investigation is ongoing. Individuals at higher risk include those 50 years old and older, cigarette smokers, and people with chronic lung disease or compromised immune systems. People living or working in the area who are experiencing these symptoms should seek medical attention with a primary care provider or seek urgent care, officials say. In 2022, at least five people died of Legionnaires' disease over the summer at a Manhattan nursing home in the city's worst outbreak, in terms of total cases, since a cooling tower in the Bronx was blamed for an infection that caused 16 deaths. Usually, about 200 to 700 people are diagnosed each year, official health data show. What is Legionnaires' disease? Legionnaires is a type of pneumonia, or a lung infection, the state DOH said. The legionella bacteria can also lead to a milder illness called Pontiac fever, which resembles flu-like symptoms. How does it spread? Legionella bacteria spread when someone inhales tiny droplets of contaminated water, commonly found in hot tubs, industrial air conditioning systems, decorative fountains, plumbing systems and even drinking water. Outbreaks often occur in large and complex water systems found in places like hotels, hospitals, and cruise ships. The bacteria can also survive and spread in soil, occasionally causing infections when people garden using contaminated soil. However, in most cases, people do not transmit Legionnaires' disease or Pontiac fever to others. What are the symptoms? Symptoms of Legionnaires disease typically appear between two to 10 days after exposure to the bacteria and can include: Headache Muscle aches Shortness of breath Cough Fever The New Jersey Department of Health noted that the symptoms can be similar to those of COVID-19 and other respiratory illnesses like the flu. Only tests ordered by a doctor can confirm a diagnosis. Who is at higher risk? Those most susceptible to Legionnaires' disease include adults over 50, individuals with weakened immune systems or chronic conditions, and smokers. It is rarer for healthy people who are exposed to the legionella bacteria to develop Legionnaires' disease. Can it be treated? Antibiotics are used to treat Legionnaires' disease, though it often requires hospitalization. Anyone suspecting exposure to Legionella or experiencing symptoms of Legionella disease or pneumonia should promptly contact a doctor. It's important to mention any exposure to Legionella, hot tub use, recent travels, or hospital stays in the past two weeks.
